title: Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
abstract: We measured serum levels of syndecan-1 in patients with multiple myeloma (MM), solitary plasmocytoma and monoclonal gammopathy of undetermined significance (MGUS). We then studied serum syndecan-1 levels in MM patients stratified by the Durie-Salmon staging system and the correlation of syndecan-1 levels with well known independent prognostic factors of MM.
authors.forename: Judit
authors.initials: J
authors.lastname: Jánosi
authors.forename: Anna
authors.initials: A
authors.lastname: Sebestyén
authors.forename: Gábor
authors.initials: G
authors.lastname: Mikala
authors.forename: Júlia
authors.initials: J
authors.lastname: Németh
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Kiss
authors.forename: István
authors.initials: I
authors.lastname: Vályi-Nagy
mesh_terms: D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood*; D009101:Multiple Myeloma / Q000097:blood*; D010265:Paraproteinemias / Q000097:blood*; D011509:Proteoglycans / Q000097:blood*; D053668:Syndecan-1; D053667:Syndecans
chemical_list: D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans